Close menu




December 2nd, 2020 | 11:18 CET

Everfuel, Fokus Mining, Bayer - you need to know that!

  • Investments
Photo credits: pixabay.com

When greed is at its greatest and development at its peak, the milkmaids buy and it's in the BILD newspaper. At the moment, the hydrogen trend has not yet reached that point. Nevertheless, it is all the more essential to take a closer look at the facts and figures. Many things that are still celebrated today can quickly turn into the negative and speaking of turning, the gold chart has held at a critical support level. Here, after the sell-off, there are good opportunities to enter gold mines once again.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA3442041024 , DE000BAY0017 , DK0061414711

Table of contents:


    Tight, tight, Everfuel

    Hydrogen is the latest hot topic with forecasts for the coming years looking relatively rosy, and government support programs worth billions support this thesis. Nevertheless one should take a closer look at the possible high flyers in the depot. Caution is advised with the Danish hydrogen specialist Everfuel. The spin-off of the well-known industry leader, Nel Asa, went public last month at the equivalent of EUR 2.00. After initial difficulties, the shares of the hydrogen filling station specialist shot up to EUR 9.20 in the middle of the week.

    Good friends stick together

    One might think that the forecasts would justify these prices. Everfuel is working in a field that can bring significant growth; however, a quadrupling within a few days is extremely rare in regulated trading. If you look at the shareholder book of the Danes, it becomes more apparent. Besides Nel Asa with almost 17%, which is intensely interested in a rising share price, the principal shareholders are E.F.-Holding, which owns nearly 68%. The supervisor behind the EF shares is none other than Everfuel's CEO, Jacob Krogsgaard, meaning that 86% of the shares are already in safe hands. In addition, there are institutional investors such as Saga Tankers, Goldman Sachs and JP Morgan. The real free float is not even 5%. That works well as long as the share price increases. But woe betide the rubber band! Then private investors are usually the ones who suffer.

    Turnaround with gold

    Gold has kept the critical support zone at $1,800 and is currently pointing north again. Gold mining stocks, which corrected in the past months, some of them strongly, are also becoming interesting again. The shares of the gold exploration Company Fokus Mining offer a promising opportunity. Here, Canadians concentrate on the acquisition and exploration of significant precious metal deposits in the province of Quebec.

    Management sees particular potential in the Galloway project acquired in August. The property is located in one of Canada's most productive mining regions. Many large projects, such as Bousquet and Noranda, have produced impressive drill results along the Cadillac-Larder Lake Fault. Over the past 100 years, more than 100 million ounces of gold have been produced from these mining sites.

    The Golden Triangle

    At the heart of the project are the three main zones, namely GP, Hendrick and Moriss, the so-called golden triangle. Although they are not directly adjacent to each other, the various gold zones, including a fourth, the Hurd Zone, could be linked together at surface and underground to form a potential corridor of approximately 1.7 kilometers.

    Ambitious goal

    The Canadians have already proven that Fokus Mining has ambitious plans. For example, a CAD 5 million financing deal was signed in mid-October, with the proceeds used immediately to start the planned 40,000m diamond drill program on the Galloway project. To date, six holes have been drilled on the Moriss gold mineralization area, and samples from four of these infill holes have been sent to the laboratory for analysis. They will test the continuity of the mineralization and try to understand the structure of the mineralization better. The Chairman of Fokus Minerals, Jean Rainville, was delighted with the developments and expects to continue to provide exciting results regularly through the end of the year.

    Another blow to the neck for Bayer

    Monsanto and no end yet. A significant settlement package agreed with US plaintiffs in June, in settlement of water allegedly contaminated with the chemical PCB, was denied by the Los Angeles Federal District Court. The judge responsible for the PCB case concerning allegedly contaminated waters now refused to agree to the compromise of the parties to the dispute. A total settlement sum of EUR 545 million was agreed with the plaintiffs. For the judge, this was, however, too little. The pharmaceutical giant has been given another deadline until the end of the year to adjust the amount upwards.

    Sale of the share tranche

    The pharmaceutical giant has secured the money that Bayer urgently needs for the increasingly expensive settlements relating to its seed business by selling Elanco shares. For the 54.5 million Elanco shares, USD 1.65 billion are now flowing into the war chest. Bayer has also announced that a further almost 8.2 million shares will be silvered in the next 30 days. With the completed sale of its veterinary medicine division to Elanco at the beginning of August, the Leverkusen-based Company received 72.9 million shares in addition to almost USD 5.2 billion in cash.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.

    Read

    Commented by Carsten Mainitz on May 10th, 2022 | 10:39 CEST

    Zalando, Aspermont, SAP - Corona and back, the stock rebound is coming!

    • Digitization
    • Investments
    • Technology

    What would society and the economy look like without digitization? The Internet, software and smartphones have become a matter of everyday life and form the basis for communication and interaction. Corona has been an accelerator in many ways. On the other hand, pandemics and war clearly show us the limits of supposedly predictable growth with scarcity prices and supply chain disruptions. At a reduced price level, it is worth looking at "digitization stocks" that offer good opportunities.

    Read

    Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

    Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

    • Biotechnology
    • Pharma
    • Investments

    Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

    Read